A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT ID: NCT06143878
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
774 participants
INTERVENTIONAL
2024-02-01
2027-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JNJ-77242113
Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24.
JNJ-77242113
JNJ-77242113 will be administered orally.
Deucravacitinib Matching Placebo
Deucravacitinib matching placebo will be administered orally.
Placebo
Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156.
JNJ-77242113
JNJ-77242113 will be administered orally.
JNJ-77242113 Matching Placebo
JNJ-77242113 matching placebo will be administered orally.
Deucravacitinib Matching Placebo
Deucravacitinib matching placebo will be administered orally.
Deucravacitinib
Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.
JNJ-77242113
JNJ-77242113 will be administered orally.
JNJ-77242113 Matching Placebo
JNJ-77242113 matching placebo will be administered orally.
Deucravacitinib
Deucravacitinib will be administered orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JNJ-77242113
JNJ-77242113 will be administered orally.
JNJ-77242113 Matching Placebo
JNJ-77242113 matching placebo will be administered orally.
Deucravacitinib
Deucravacitinib will be administered orally.
Deucravacitinib Matching Placebo
Deucravacitinib matching placebo will be administered orally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
* Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
* Total investigator global assessment (IGA) \>=3 at screening and baseline
* Candidate for phototherapy or systemic treatment for plaque psoriasis
Exclusion Criteria
* Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
* A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention
* Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Research & Development, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Research & Development, LLC Clinicaltrial
Role: STUDY_DIRECTOR
Janssen Research & Development, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Dermatology Specialists
Phoenix, Arizona, United States
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona, United States
Johnson Dermatology
Fort Smith, Arkansas, United States
First OC Dermatology
Fountain Valley, California, United States
Center for Dermatology Clinical Research
Fremont, California, United States
Integrative Skin Science and Research
Sacramento, California, United States
Southern California Dermatology
Santa Ana, California, United States
Clinical Science Institute
Santa Monica, California, United States
Driven Research LLC
Coral Gables, Florida, United States
Ziaderm Research LLC
North Miami Beach, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Forcare Clinical Research Inc
Tampa, Florida, United States
Hamilton Research LLC
Alpharetta, Georgia, United States
Skin Care Physicians of Georgia
Macon, Georgia, United States
DeNova Research
Chicago, Illinois, United States
Arlington Dermatology
Rolling Meadows, Illinois, United States
Northshore Medical Group
Skokie, Illinois, United States
Dundee Dermatology
West Dundee, Illinois, United States
Dawes Fretzin Clinical Research Group LLC
Indianapolis, Indiana, United States
Indiana Clinical Trial Center
Plainfield, Indiana, United States
Dermatology Specialists
Louisville, Kentucky, United States
Dermatology and Advanced Aesthetics
Lake Charles, Louisiana, United States
Tufts Medical Center
Boston, Massachusetts, United States
David Fivenson MD, Dermatology
Ann Arbor, Michigan, United States
Michigan Center of Medical Research
Clarkston, Michigan, United States
Henry Ford Medical Center
Detroit, Michigan, United States
Hamzavi Dermatology
Fort Gratiot, Michigan, United States
MediSearch Clinical Trials
Saint Joseph, Missouri, United States
Skin Specialists
Omaha, Nebraska, United States
Fife Dermatology
Las Vegas, Nevada, United States
StracSkin
Portsmouth, New Hampshire, United States
Schweiger Dermatology Group
East Windsor, New Jersey, United States
Schweiger Dermatology Group
Hackensack, New Jersey, United States
Derm Research Center of New York, Inc.
Stony Brook, New York, United States
Wilmington Dermatology Center
Wilmington, North Carolina, United States
Oakview Dermatology
Athens, Ohio, United States
Optima Research
Boardman, Ohio, United States
Central Sooner Research
Oklahoma City, Oklahoma, United States
Oregon Medical Research Center
Portland, Oregon, United States
Health Concepts
Rapid City, South Dakota, United States
Modern Research Associates
Dallas, Texas, United States
Center for Clinical Studies
Houston, Texas, United States
Austin Institute for Clinical Research
Houston, Texas, United States
Austin Institute for Clinical Research
Pflugerville, Texas, United States
Progressive Clinical Research
San Antonio, Texas, United States
Texas Dermatology and Laser Specialists
San Antonio, Texas, United States
Center for Clinical Studies
Webster, Texas, United States
National Clinical Research
Richmond, Virginia, United States
Frontier Derm Partners CRO, LLC
Mill Creek, Washington, United States
Premier Clinical Research
Spokane, Washington, United States
Instituto Medico De Alta Complejidad (IMAC)
Buenos Aires, , Argentina
ARCIS Salud SRL Aprillus asistencia e investigacion
Buenos Aires, , Argentina
Halitus Instituto Medico S.A. - Dermatologia y Estetica
Caba, , Argentina
Hospital Italiano de Buenos Aires
Caba, , Argentina
Instituto de Neumonologia y Dermatologia
CABA, , Argentina
Hospital Italiano de La Plata
La Plata, , Argentina
Instituto Caici Srl.
Rosario, , Argentina
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, , Argentina
North Eastern Health Specialists
Campbelltown, , Australia
Paratus Clinical Research Woden
Canberra, , Australia
Sinclair Dermatology
East Melbourne, , Australia
Skin Health Institute Inc.
Melbourne, , Australia
Veracity Clinical Research
Woolloongabba, , Australia
Fundacao do ABC Centro Universitario FMABC
Santo André, , Brazil
Enverus Medical
Surrey, British Columbia, Canada
Karma Clinical Trials Inc.
St. John's, Newfoundland and Labrador, Canada
CCA Medical Research Corporation
Ajax, Ontario, Canada
SimcoDerm Medical and Surgical Dermatology Centre
Barrie, Ontario, Canada
Dermatrials Research
Hamilton, Ontario, Canada
York Dermatology Clinic and Research Centre
Richmond Hill, Ontario, Canada
Alliance Clinical Trials
Waterloo, Ontario, Canada
XLR8 Medical Research
Windsor, Ontario, Canada
ISA - Interdisciplinary Study Association GmbH
Berlin, , Germany
Hautarztpraxis
Bramsche, , Germany
Klinische Forschung Dresden GmbH
Dresden, , Germany
Praxis für Dermatologie und Venerologie
Dresden, , Germany
Universitaetsklinikum Duesseldorf
Düsseldorf, , Germany
Universitaetsklinikum Hamburg Eppendorf
Hamburg, , Germany
MensingDerma research GmbH
Hamburg, , Germany
Universitaetsklinikum Schleswig Holstein Campus Kiel
Kiel, , Germany
Studienzentrum Dr Schwarz Germany
Langenau, , Germany
Universitatsklinikum Leipzig AOR
Leipzig, , Germany
Universitatsklinikum Schleswig Holstein Campus Lubeck
Lübeck, , Germany
Universitaetsklinikum Mannheim
Mannheim, , Germany
Klinik und Poliklinik fur Dermatologie und Allergologie am Biederstein
München, , Germany
Hautarztpraxis
Potsdam, , Germany
Universitaetsmedizin Rostock
Rostock, , Germany
Pecsi Tudomanyegyetem
Borgyogyaszati Klinika, , Hungary
Obudai Egeszsegugyi Centrum Kft
Budapest, , Hungary
Derma-B Kft
Debrecen, , Hungary
Debreceni Egyetem Klinikai Kozpont
Debrecen, , Hungary
Somogy Varmegyei Kaposi Mor Oktato Korhaz
Kaposvár, , Hungary
SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati és Allergologiai Klinika
Szeged, , Hungary
Allergo-Derm Bakos Kft.
Szolnok, , Hungary
Medmare Egeszsegugyi Es Szolgaltato Bt.
Veszprém, , Hungary
Fukuoka University Hospital
Fukuoka, , Japan
Hino Dermatology Clinic
Fukutsu, , Japan
Gifu University Hospital
Gifu, , Japan
University of the Ryukyus Hospital
Ginowan, , Japan
Gunma University Hospital
Gunma, , Japan
JR Sapporo Hospital
Hokkaido, , Japan
Asahikawa Medical University Hospital
Hokkaido, , Japan
Tokai University Hospital
Isehara, , Japan
Teikyo University Hospital
Itabashi Ku, , Japan
St Marianna University Hospital
Kawasaki, , Japan
Hospital of the University of Occupational and Enviromental Health
Kitakyushu-shi, , Japan
Nagoya City University Hospital
Nagoya, , Japan
Takagi Dermatological Clinic
Obihiro Shi, , Japan
Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
Osaka, , Japan
Kindai University Hospital
Sakai, , Japan
Kume Clinic
Sakaishi, , Japan
Sapporo Skin Clinic
Sapporo, , Japan
Tohoku University Hospital
Sendai, , Japan
The University of Osaka Hospital
Suita, , Japan
Jitaikai Tachikawa dermatology clinic
Tachikawa, , Japan
Shirasaki Dermatology Clinic
Takaoka Shi, , Japan
Tokyo Medical University Hospital
Tokyo, , Japan
Mie University Hospital
Tsu, , Japan
Osteo-Medic s.c A. Racewicz, J Supronik
Bialystok, , Poland
Specderm Poznanska sp j
Bialystok, , Poland
Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
Elblag, , Poland
Centrum Medyczne dr Rajzer Sp z o o
Krakow, , Poland
Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
Krakow, , Poland
Centrum Medyczne Promed
Krakow, , Poland
Dermed Centrum Medyczne Sp z o o
Lodz, , Poland
Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
Lodz, , Poland
Dermodent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski S C
Osielsko, , Poland
SOLUMED Centrum Medyczne
Poznan, , Poland
Clinical Research Center sp z o o MEDIC R s k
Poznan, , Poland
Dorota Bystrzanowska High-Med. Przychodnia Specjalistyczna
Warsaw, , Poland
Klinika Ambroziak Dermatologia
Warsaw, , Poland
DERMMEDICA Sp.z o.o.
Wroclaw, , Poland
Wro Medica
Wroclaw, , Poland
Centrum Medyczne Oporow
Wroclaw, , Poland
Pusan National University Hospital
Busan, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Hanyang University Medical Center
Seoul, , South Korea
Konkuk University Medical Center
Seoul, , South Korea
The Catholic University of Korea Seoul St Marys Hospital
Seoul, , South Korea
Kyung Hee University Hospital
Seoul, , South Korea
Hosp. Gral. Univ. Dr. Balmis
Alicante, , Spain
Hosp. Univ. de Cruces
Barakaldo, , Spain
Hosp. de La Santa Creu I Sant Pau
Barcelona, , Spain
Hosp. Univ. San Cecilio
Granada, , Spain
Hosp. Univ. de Bellvitge
L'Hospitalet de Llobregat, , Spain
Grupo Dermatologico Y Estetico Pedro Jaen
Madrid, , Spain
Hosp. Univ. de La Princesa
Madrid, , Spain
Hosp. Gral. Univ. Gregorio Maranon
Madrid, , Spain
Hosp. Univ. Infanta Leonor
Madrid, , Spain
Hosp. Univ. 12 de Octubre
Madrid, , Spain
Hosp. Univ. de La Paz
Madrid, , Spain
Hosp. Univ. I Politecni La Fe
Valencia, , Spain
Chang Kung Memorial Hospital
Kaohsiung City, , Taiwan
Taipei Medical University Shuang Ho Hospital
New Taipei City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Mackay Memorial Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
National Taiwan University Hospital Hsin Chu Branch
Taoyuan District, , Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan District, , Taiwan
Guys and St Thomas NHS Foundation Trust
London, , United Kingdom
Royal Berkshire Hospital
Reading, , United Kingdom
Salford Royal Hospital
Salford, , United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025 Sep 27;406(10510):1363-1374. doi: 10.1016/S0140-6736(25)01576-4. Epub 2025 Sep 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
77242113PSO3002
Identifier Type: OTHER
Identifier Source: secondary_id
77242113PSO3002
Identifier Type: -
Identifier Source: org_study_id